Systemic Medication Adjustment and Short-Term Relapse of Cytomegalovirus Retinitis After Allogeneic Hematopoietic Stem Cell Transplantation: A Research Communication.
- 1Department of Ophthalmology, Peking University People's Hospital, Beijing 100044, China.
- 2Beijing Key Laboratory of Ocular Disease and Optometry Science, Peking University People's Hospital, Beijing 100044, China.
Abstract
Background: Cytomegalovirus retinitis (CMVR) remains a sight-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Systemic antiviral, immunosuppressive, and anti-infective regimens are often modified because of transplant-related complications, but the association between these modifications and ocular relapse remains unclear. Methods: We analyzed a prospective cohort of 44 patients with CMVR after allo-HSCT (65 affected eyes) who were followed for three months after discontinuation of local antiviral therapy. The primary analysis used Cox proportional hazards regression at the eye level with robust standard errors clustered by patient. Exact dates of the first systemic medication adjustment were retrieved, and additional time-dependent Cox and patient-level time-to-first-relapse Cox analyses were performed. Results: During follow-up, 24 eyes from 19 patients relapsed, and 18 patients underwent systemic medication adjustment. The first adjustment occurred a median of 25.5 days after discontinuation of local therapy (range, 7 to 72 days). Among the 13 adjusted patients who relapsed, all first adjustments preceded relapse, with a median adjustment-to-relapse interval of 15 days (range, 3 to 52 days). In the primary model, medication adjustment was associated with relapse (HR, 8.254; 95% CI, 2.656 to 25.645; p < 0.001), as was baseline aqueous IL-8 (HR, 1.190 per 100 pg/mL; 95% CI, 1.088 to 1.301; p < 0.001). In the time-dependent eye-level analysis, medication adjustment remained associated with relapses (HR, 11.360; 95% CI, 4.330 to 29.803; p < 0.001). A patient-level time-to-first-relapse Cox analysis showed a similar association (HR, 4.477; 95% CI, 1.688 to 11.878; p = 0.003). Conclusions: Systemic medication adjustment was associated with short-term CMVR relapse after allo-HSCT. Because treatment changes were clinically indicated and heterogeneous, the findings remain associative, and confounding by indication cannot be excluded.
Related
- Endoscopic Findings Can Help Predict Cytomegalovirus Colitis after Hematopoietic Stem Cell Transplantation.
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- Selection bias in Mendelian randomization studies with adjustment for medication use
- A randomized controlled trial of a multidisciplinary collaborative fatigue management program for patients undergoing hematopoietic stem cell transplantation: study protocol
- Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
BibTeX
@article{wu2026systemic,
title = {{Systemic Medication Adjustment and Short-Term Relapse of Cytomegalovirus Retinitis After Allogeneic Hematopoietic Stem Cell Transplantation: A Research Communication.}},
author = {Shuo Wu and Yihong Ding and Jing Hou},
journal = {Biomedicines},
year = {2026},
month = sep,
doi = {10.3390/biomedicines14102189},
url = {https://europepmc.org/article/MED/42939995},
note = {CC BY},
}
RIS
TY - JOUR
TI - Systemic Medication Adjustment and Short-Term Relapse of Cytomegalovirus Retinitis After Allogeneic Hematopoietic Stem Cell Transplantation: A Research Communication.
AU - Shuo Wu
AU - Yihong Ding
AU - Jing Hou
PY - 2026
DA - 2026/09/28
JO - Biomedicines
DO - 10.3390/biomedicines14102189
UR - https://europepmc.org/article/MED/42939995
AB - Background: Cytomegalovirus retinitis (CMVR) remains a sight-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Systemic antiviral, immunosuppressive, and anti-infective regimens are often modified because of transplant-related complications, but the association between these modifications and ocular relapse remains unclear. Methods: We analyzed a prospective cohort of 44 patients with CMVR after allo-HSCT (65 affected eyes) who were followed for three months after discontinuation of local antiviral therapy. The primary analysis used Cox proportional hazards regression at the eye level with robust standard errors clustered by patient. Exact dates of the first systemic medication adjustment were retrieved, and additional time-dependent Cox and patient-level time-to-first-relapse Cox analyses were performed. Results: During follow-up, 24 eyes from 19 patients relapsed, and 18 patients underwent systemic medication adjustment. The first adjustment occurred a median of 25.5 days after discontinuation of local therapy (range, 7 to 72 days). Among the 13 adjusted patients who relapsed, all first adjustments preceded relapse, with a median adjustment-to-relapse interval of 15 days (range, 3 to 52 days). In the primary model, medication adjustment was associated with relapse (HR, 8.254; 95% CI, 2.656 to 25.645; p < 0.001), as was baseline aqueous IL-8 (HR, 1.190 per 100 pg/mL; 95% CI, 1.088 to 1.301; p < 0.001). In the time-dependent eye-level analysis, medication adjustment remained associated with relapses (HR, 11.360; 95% CI, 4.330 to 29.803; p < 0.001). A patient-level time-to-first-relapse Cox analysis showed a similar association (HR, 4.477; 95% CI, 1.688 to 11.878; p = 0.003). Conclusions: Systemic medication adjustment was associated with short-term CMVR relapse after allo-HSCT. Because treatment changes were clinically indicated and heterogeneous, the findings remain associative, and confounding by indication cannot be excluded.
SN - 2227-9059
ER -